Drugs Made In America Acquisition Corp. $DMAA Stock Position Reduced by ATW Spac Management LLC

ATW Spac Management LLC decreased its stake in Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) by 12.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 500,000 shares of the company’s stock after selling 70,000 shares during the quarter. Drugs Made In America Acquisition makes up about 6.7% of ATW Spac Management LLC’s holdings, making the stock its 3rd biggest position. ATW Spac Management LLC owned approximately 1.71% of Drugs Made In America Acquisition worth $5,135,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Wolverine Asset Management LLC raised its holdings in shares of Drugs Made In America Acquisition by 22.2% during the third quarter. Wolverine Asset Management LLC now owns 1,249,128 shares of the company’s stock worth $12,829,000 after acquiring an additional 227,222 shares in the last quarter. Karpus Management Inc. increased its position in Drugs Made In America Acquisition by 18.1% in the 2nd quarter. Karpus Management Inc. now owns 2,744,109 shares of the company’s stock worth $27,990,000 after purchasing an additional 420,075 shares during the last quarter. Clear Street LLC acquired a new position in Drugs Made In America Acquisition in the 2nd quarter worth about $1,149,000. Boothbay Fund Management LLC purchased a new stake in shares of Drugs Made In America Acquisition during the 2nd quarter worth about $5,814,000. Finally, Radcliffe Capital Management L.P. acquired a new stake in shares of Drugs Made In America Acquisition during the 2nd quarter valued at about $1,293,000.

Drugs Made In America Acquisition Price Performance

Shares of NASDAQ DMAA opened at $10.46 on Wednesday. The business’s 50-day simple moving average is $10.42 and its 200-day simple moving average is $10.34. Drugs Made In America Acquisition Corp. has a 52 week low of $9.96 and a 52 week high of $10.48.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Drugs Made In America Acquisition in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.